Association of ADIPOQ gene polymorphisms and coronary artery disease risk: A meta-analysis based on 12 465 subjects

Clinical and genetic predictors of weight gain in patients diagnosed with breast cancer

“…Aside from rs822396, the other significant genetic findings at 12- or 18-month time points were interactions among rs266729 ( ADIPOQ ), rs1342387 ( ADIPOR1 ), and rs7539542 ( ADIPOR1 ). In addition to also having associations with risk of prostate and colon cancer, type 2 diabetes, and ischaemic stroke, these SNPs have been linked to coronary artery disease, hypertension, and efficacy of weight loss products such as sibutramine (Hegener et al , 2006; Siitonen et al , 2006; Kaklamani et al , 2008b; Hsiao et al , 2010; Han et al , 2011; He et al , 2011; Liu et al , 2011; Kaklamani et al , 2011b; Mather et al , 2012; Mtiraoui et al , 2012; Yang et al , 2012; Zhang et al , 2012). Receiver operating characteristic analysis of an epistatic model of significant SNPs on multivariate analysis only showed AUC of 0.24 for 18-month weight gain.…”

Association of adiponectin gene polymorphisms and additional gene-gene interaction with nonalcoholic fatty liver disease in the Chinese Han population

“…Variant alleles at rs266729, which is associated with lower adiponectin levels, have been shown to be related to obesity [10], type 2 diabetes (T2DM) [11], and insulin sensitivity [12]. Another variant, rs1501299, is correlated with decreased adiponectin expression, which might in turn lead to increased body weight and insulin resistance [13,14]. However, the variant rs822393 (-4522 C/T) was not well reported in the Chinese population.…”

Adiponectin gene (ADIPOQ) polymorphisms correlate with the progression of nephropathy in Taiwanese male patients with type 2 diabetes

“…The adiponectin gene (ADIPOQ), located on human chromosome 3q27, has been mapped as a genetic susceptibility locus for obesity, insulin resistance, T2D, and cardiovascular disease (CVD) in different populations [8,9]. Adiponectin, encoded by ADIPOQ, is lower in patients with T2D…”